Paper Details

  1. Home
  2. Paper Details

Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.

Author: BergerDietmar, ChenMon-Gy, ChenYuhchyau, HenkeMichael, HickeyMichael, KimHarold E, LeQuynh-Thu, LizambriRichard, MoMay, MuraközyGyörgyi, ReinischSabine, SchneiderCharles J, SkladowskiKrzysztof

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, placebo-controlled trial evaluated the efficacy and safety of palifermin for reducing oral mucositis (OM) associated with chemoradiotherapy for head and neck cancer. Palifermin was found to significantly reduce the incidence of severe OM and delay time to severe OM, but the differences in xerostomia, opioid analgesic use, and chemoradiotherapy compliance were not significant.
Paper Details　
Original Abstract of the Article :
PURPOSE: Oral mucositis (OM) is a debilitating toxicity of chemoradiotherapy for head and neck cancer (HNC). This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of palifermin to reduce OM associated with definitive chemoradiotherapy for locally advanced HNC. PA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2010.32.4095

データ提供：米国国立医学図書館（NLM）

Palifermin: A Potential Protector Against Mucositis in Head and Neck Cancer

Head and neck cancer treatment often involves chemoradiotherapy, which can lead to debilitating side effects, including oral mucositis. This study, published in the field of Head and Neck Cancer, explores the efficacy and safety of palifermin, a recombinant human keratinocyte growth factor, in reducing oral mucositis associated with definitive chemoradiotherapy for locally advanced head and neck cancer. The researchers conducted a randomized, placebo-controlled, double-blind study to assess the impact of palifermin on the incidence and severity of oral mucositis.

Palifermin: A Potential Ally in Mitigating Oral Mucositis

The study's findings suggest that palifermin may be effective in reducing the incidence of severe oral mucositis in patients receiving chemoradiotherapy for head and neck cancer. Palifermin was found to significantly lower the incidence of severe oral mucositis compared to placebo. These findings suggest that palifermin could potentially improve the quality of life for patients undergoing this challenging treatment, reducing pain, discomfort, and nutritional difficulties.

Navigating the Desert of Head and Neck Cancer Treatment

The study's findings offer a ray of hope in the desert of head and neck cancer treatment, suggesting that palifermin could be a valuable tool for managing oral mucositis, a common and debilitating side effect of chemoradiotherapy. However, further research is needed to fully understand the long-term effects of palifermin and its optimal use in the management of head and neck cancer.

Dr. Camel's Conclusion

This study, like a refreshing oasis in the vast desert of head and neck cancer treatment, reveals the potential of palifermin to reduce the incidence of severe oral mucositis, a significant side effect of chemoradiotherapy. The researchers' findings suggest that palifermin could potentially improve the quality of life for patients undergoing this challenging treatment, offering a glimmer of hope in the fight against head and neck cancer.

Date :
  1. Date Completed 2011-09-20
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

21670453

DOI: Digital Object Identifier

10.1200/JCO.2010.32.4095

Related Literature

Article Analysis
・Side Effects of palifermin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.